CLOUDBREAK THERAPEUTICS
Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.
CLOUDBREAK THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2015-09-01
Address:
Irvine, California, United States
Country:
United States
Website Url:
http://www.cloudbreaktherapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
171.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
Rain Therapeutics
Rain Therapeutics is a operator of a clinical stage biotechnology company.
Current Employees Featured
Founder
Investors List
EFung Capital
EFung Capital investment in Series C - Cloudbreak Therapeutics
Industrial Securities Capital
Industrial Securities Capital investment in Series C - Cloudbreak Therapeutics
Grand Pharmaceutical
Grand Pharmaceutical investment in Series C - Cloudbreak Therapeutics
CDF-Capital
CDF-Capital investment in Series C - Cloudbreak Therapeutics
CDH Investments
CDH Investments investment in Series C - Cloudbreak Therapeutics
Yuejun Investment
Yuejun Investment investment in Series C - Cloudbreak Therapeutics
Dyee Capital
Dyee Capital investment in Series C - Cloudbreak Therapeutics
Yingke Capital
Yingke Capital investment in Series C - Cloudbreak Therapeutics
ShenZhen GTJA Investment Group
ShenZhen GTJA Investment Group investment in Series C - Cloudbreak Therapeutics
CCB International
CCB International investment in Series C - Cloudbreak Therapeutics
Official Site Inspections
http://www.cloudbreaktherapeutics.com
- Host name: 217.70.196.104.bc.googleusercontent.com
- IP address: 104.196.70.217
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Cloudbreak Therapeutics"
Cloudbreak Therapeutics - Crunchbase Company Profile & Funding
Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Cloudbreak Therapeutics operates a capital efficient business model based โฆSee details»
Cloudbreak Therapeutics Company Profile | Management and
Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development.See details»
CLOUDBREAK THERAPEUTICS LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CLOUDBREAK THERAPEUTICS LLC of Irvine, CA. Get the latest business insights from Dun โฆSee details»
Overview, News & Similar companies - ZoomInfo.com
View Cloudbreak Therapeutics (www.cloudbreaktherapeutics.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as โฆSee details»
CLOUDBREAK THERAPEUTICS LLC - VentureRadar
DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and production in Denmark and โฆSee details»
About - Cloudbreak Pharma ๆจๅบท่งไบ
We are a clinical stage global biotechnology company developing ophthalmic drugs for chronic eye diseases which are often with few treatment options.See details»
Cloudbreak Therapeutics - Funding, Financials, Valuation & Investors
Cloudbreak Therapeutics is a clinical stage biotechnology company. How much funding has this organization raised over time? ShowSee details»
Cloudbreak Pharma - LinkedIn
We are a clinical stage global biotechnology company developing ophthalmic drugs for chronic eye diseases which are often with few treatment options.See details»
Cloudbreak Therapeutics, LLC | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Cloudbreak Therapeutics - Craft
See insights on Cloudbreak Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Cloudbreak Receives U.S. Food and Drug Administration Clearance โฆ
Irvine, CA โ November 30, 2020 โ Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received โฆSee details»
Series C - Cloudbreak Therapeutics - 2022-01-01 - Crunchbase
Jan 1, 2022 Organization Name . Cloudbreak Therapeutics . Announced Date Jan 1, 2022; Funding Type Series C; Funding Stage Late Stage Venture; Money Raised . $130M. โฆSee details»
Cloudbreak Therapeutics Stock Price, Funding, Valuation, Revenue ...
Jan 1, 2022 cloudbreaktherapeutics.com. Overview & Products; Financials; People; Total Raised $171.26M. Investors Count 15. Funding, Valuation & Revenue. 3 Fundings. โฆSee details»
Van Dinh - Co-founder, Chief Operating Officer - Crunchbase
Primary Organization . Cloudbreak Therapeutics . Location Irvine, California, United States; Regions Greater Los Angeles Area, West Coast, Western US; Gender Male; LinkedIn View on โฆSee details»
Technology - Cloudbreak Pharma
We formulated a potent multi-kinase inhibitor which can block VEGFR (1-3), PDGFR (,), FGFR (1-3) into a topical eye drop to treat pterygium, pinguecula, glaucoma filtration surgery, and โฆSee details»
Van Dinh, MBA - Cloudbreak Therapeutics LLC | LinkedIn
Aug 16, 2024 25 years experiences in the pharmaceutical and biotechnology industry<br>Experiencedโฆ · Experience: Cloudbreak Therapeutics LLC · Education: Webster โฆSee details»
News Archives - Cloudbreak Pharma
Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical treatment of pterygium. Santen and Cloudbreak execute a new licensing agreement for CBT-001, a topical โฆSee details»
Cloudbreak Pharma is developing novel drugs for MGD : r/Dryeyes โฆ
They are developing two similar drugs, named CBT-006 and CBT-008. Both have already finished Phase II studies (no results published): Physicians often prescribe artificial tears to provide โฆSee details»
Pipeline - Cloudbreak Pharma
Healthcare providers, visit our ophthalmology pipeline to identify potential solutions for patients and discover our full line of investigational drugsSee details»